These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 9187614)

  • 21. Precipitation of amphotericin B from i.v. fat emulsion.
    Heide PE
    Am J Health Syst Pharm; 1997 Jun; 54(12):1449. PubMed ID: 9194992
    [No Abstract]   [Full Text] [Related]  

  • 22. Acute renal failure with amphotericin B in lipid emulsion.
    Gales MA; Gales BJ; Alford KM
    Ann Pharmacother; 1996 Sep; 30(9):1036. PubMed ID: 8876871
    [No Abstract]   [Full Text] [Related]  

  • 23. Toxicity of amphotericin B emulsion formulations.
    Washington C; Lance M; Davis SS
    J Antimicrob Chemother; 1993 May; 31(5):806-8. PubMed ID: 8380021
    [No Abstract]   [Full Text] [Related]  

  • 24. Amphotericin B toxicity reduced by administration in fat emulsion.
    Anderson RP; Clark DA
    Ann Pharmacother; 1995 May; 29(5):496-500. PubMed ID: 7655134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Lipid derivatives of amphotericin B in treatment of systemic candidiasis].
    Rosenthal E
    Presse Med; 2000 Mar; 29(8):428. PubMed ID: 10738509
    [No Abstract]   [Full Text] [Related]  

  • 26. Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature.
    Wasan KM; Sivak O; Bartlett K; Wasan EK; Gershkovich P
    Drug Dev Ind Pharm; 2015; 41(9):1425-30. PubMed ID: 25170660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment of visceral leishmaniasis with high-dose amphotericin B diluted in fat emulsion: a case report.
    Herbrecht R; Sosa C; Himy R; Villard O
    Trans R Soc Trop Med Hyg; 1996; 90(3):322-3. PubMed ID: 8758094
    [No Abstract]   [Full Text] [Related]  

  • 28. [Amphotericin B into parenteral lipid emulsions. Galenic stability of mixtures. Preliminary results].
    Blancard A; Monges P; Lacarelle B; Denis JP; Bongrand MC; Ragon CH; Gouin F
    Pathol Biol (Paris); 1996 May; 44(5):384-8. PubMed ID: 8758481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amphotericin B releasing topical nanoemulsion for the treatment of candidiasis and aspergillosis.
    Sosa L; Clares B; Alvarado HL; Bozal N; Domenech O; Calpena AC
    Nanomedicine; 2017 Oct; 13(7):2303-2312. PubMed ID: 28712917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar.
    Sundar S; Chakravarty J; Agarwal D; Shah A; Agrawal N; Rai M
    Trop Med Int Health; 2008 Sep; 13(9):1208-12. PubMed ID: 18664241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Various indicators of amphotericin B pharmacokinetics in infants with Candida meningitis during the 1st year of life].
    Raĭner MA
    Antibiot Med Biotekhnol; 1985 Feb; 30(2):128-31. PubMed ID: 4004186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Amphotericin B in treatment of candidiasis in children].
    Pisiewicz K; Sliwa Z; Zebrak J; Zuk E; Zulawska-Dutkiewicz A
    Pediatr Pol; 1972 Apr; 47(4):455-9. PubMed ID: 5022932
    [No Abstract]   [Full Text] [Related]  

  • 33. Liposomal amphotericin B in neonates with invasive candidiasis.
    Al Arishi H; Frayha HH; Kalloghlian A; Al Alaiyan S
    Am J Perinatol; 1998; 15(11):643-8. PubMed ID: 10064206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Amphotericin B-intralipid 20% combination. In vivo evaluation of its tolerability].
    Débat Zoguéreh D; Poignard P; Sorriaux A; Brouqui P
    Ann Med Interne (Paris); 1997; 148(1):100-2. PubMed ID: 9137701
    [No Abstract]   [Full Text] [Related]  

  • 35. Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients.
    Joly V; Geoffray C; Reynes J; Goujard C; Méchali D; Maslo C; Raffi F; Yeni P
    J Antimicrob Chemother; 1996 Jul; 38(1):117-26. PubMed ID: 8858463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Amphotericin in intravenous perfusions in moniliasis].
    Cordonnier V; Lundy-Mahieu M; De Beer P; Duflos M
    Bull Soc Fr Dermatol Syphiligr; 1970; 77(2):175-84. PubMed ID: 5460207
    [No Abstract]   [Full Text] [Related]  

  • 37. Management of Candida peritonitis with intravenous amphotericin: Peritoneal fluid antibiotic levels.
    Levin RM; Jason C; Black S; Nickolai D; Potter D; Grossman M
    Clin Pediatr (Phila); 1982 Nov; 21(11):693-5. PubMed ID: 7127992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of neonatal candidiasis with liposomal amphotericin B.
    Kapoor D
    Indian Pediatr; 2004 May; 41(5):522-3; author reply 523-5. PubMed ID: 15181316
    [No Abstract]   [Full Text] [Related]  

  • 39. Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B.
    Barcia JP
    Pharmacotherapy; 1998; 18(4):874-6. PubMed ID: 9692667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid emulsions as drug delivery systems.
    Davis SS; Washington C; West P; Illum L; Liversidge G; Sternson L; Kirsh R
    Ann N Y Acad Sci; 1987; 507():75-88. PubMed ID: 3327420
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.